Insights into the pharmaceutical properties and in silico study of novel hydrazone derivatives
Hiba H Ibraheem, Batool K Queen, Matheel D Al-Sabti, Ali A Issa, Yasameen K Al-Majedy, Majid S Jabir, Ghassan M Sulaiman, Buthenia A Hasoon, Merriam M Eshaq, Kareem H Jawad, Sabrean F Jawad, Hayder A Fawzi, Muhammad Shuaib, Mazin A A Najm, Ayman A Swelum · 2024
Read Insights into the pharmaceutical properties and in silico study of novel hydrazone derivatives by Hiba H Ibraheem, Batool K Queen, Matheel D Al-Sabti, Ali A Issa, Yasameen K Al-Majedy, Majid S Jabir, Ghassan M Sulaiman, Buthenia A Hasoon, Merriam M Eshaq, Kareem H Jawad, Sabrean F Jawad, Hayder A Fawzi, Muhammad Shuaib, Mazin A A Najm, Ayman A Swelum (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11612229.txt.
Description
Hiba Ibraheem led a team that made, in two thousand twenty-four, new hydrazone drugs and probed how they might act. The group has known worth in care. The team built their set in three steps, then ran lab tests and computer sums.
First, hydrazine met a carbonyl compound in warm ethanol to form the base, called H1. Next, H1 met indole to form a Schiff base, H2. In step three, H1 met thiophene to form H3. Tests with light and with magnets checked each new drug. H2 and H3 fought cell harm from rust-like stress, more so at higher dose. They also slowed the growth of three germs: Staphylococcus aureus, Escherichia coli, and Candida albicans. The sums showed firm holds on target sites in cells. That firm hold marks the set as a lead worth more work as a drug for colon cancer.
Catalog record
| CREATOR | Hiba H Ibraheem, Batool K Queen, Matheel D Al-Sabti, Ali A Issa, Yasameen K Al-Majedy, Majid S Jabir, Ghassan M Sulaiman, Buthenia A Hasoon, Merriam M Eshaq, Kareem H Jawad, Sabrean F Jawad, Hayder A Fawzi, Muhammad Shuaib, Mazin A A Najm, Ayman A Swelum |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |